Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846137 | 1.00 | KCNH2 (0.41) | KCNH2MMP2MMP9MMP12SCN4A | |
| SCHEMBL12846088 | 1.00 | KCNH2 (0.41) | KCNH2MMP2MMP9MMP12SCN4A | |
| SCHEMBL14465175 | 0.76 | KCNH2 (0.42) | KCNH2MMP2MMP9MMP12LMNA | |
| SCHEMBL12846320 | 0.75 | SCN4A (0.50) | SCN4ASMN1; SMN2LMNAKDM4ETHRB | |
| SCHEMBL12785396 | 0.74 | TACR1 (0.44) | SCN4ANPC1RAB9A | |
| SCHEMBL12785413 | 0.74 | TACR1 (0.44) | SCN4ANPC1RAB9A | |
| SCHEMBL12785411 | 0.74 | TACR1 (0.44) | SCN4ANPC1RAB9A | |
| SCHEMBL9512258 | 0.69 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL12846089 | 0.69 | KCNH2 (0.40) | KCNH2KDM4ETHRBTDP1 | |
| SCHEMBL12784448 | 0.69 | ADRB2 (0.48) | KCNH2LMNAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | KCNH2 2368/4885MMP2 4305/4885MMP9 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.